1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legislation

FDA Agrees To Waive User Fees For Reviews Of Lab-Developed Tests

Although FDA is still developing its lab-developed test regulatory framework, it has agreed not to collect user fees to support its planned review of the tests.

FDA will not collect user fees to support its planned pre-market reviews of laboratory-developed tests, according to a draft agreement with industry.

The agency and industry agreed to a draft commitment letter and proposed legislative language for the reauthorization of the Medical...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

CMS Announces $50B In Grants For Rural Health Transformation

AdvaMed has praised CMS’ Rural Health Transformation Program, which will allocate $50 billion over five years to enhance rural healthcare. States can apply for grants by Nov. 5 to develop sustainable healthcare systems and improve patient outcomes.

PathAI Expands AISight Dx Label With PCCP-Guided Addition Of Roche Scanners

 
• By Natasha Barrow

Roche’s scanners have been integrated with PathAI’s AISight Dx system. The system’s FDA-cleared PCCP allows new components to be validated and integrated without additional FDA clearance. Eric Walk, chief medical officer, hints at future biopharma companion diagnostic collaborations.

NextGen Dx Panel Expects Continued Limbo On LDT Regulation

 
• By Elizabeth Orr

A recent conference panel discussed the stagnation in diagnostics regulation, highlighting the FDA's failed regulatory efforts on lab-developed tests. Political and legislative challenges hinder other reforms, and concerns over Medicare reimbursement cuts loom for the clinical lab industry.

No EUDAMED, No Market: ‘Waiting Until Mandatory Deadline Is Risky’

 
• By Natasha Barrow

EirMed CEO Richard Houlihan warns that EUDAMED (the European database on medical devices) publication delays may harm medical device manufacturers. Currently, only a fraction of the required uploads have occurred, creating potential compliance risks as the mandatory deadline approaches.

More from Policy & Regulation

Blood Sugar Spike Risk Leads To Recall Of Tandem Insulin Pumps

 
• By Brian Bossetta

Tandem Diabetes Care initiated a recall last month of several t:slim X2 insulin pumps due to a “malfunction 16” error that can cause the pumps to shut down. The problem is triggered by wiring within the device speaker.

FTC’s New Healthcare Division Chief Is Former Antitrust Prosecutor

 
• By Malcolm Spicer

Emma Mittelstaedt Burnham prosecuted antitrust violations in healthcare sector in her previous work at DoJ, including leading investigation into antitrust cartels in the generic pharmaceutical industry.

From Prioritizing Funding To Non-Animal Data, FDA Receives A Range Of Comments

 
• By Brian Bossetta

The US FDA received over two dozen comments from stakeholders on the next round of the medical device user fee amendments, which will establish funding for fiscal years 2028 through 2032.